Aileron Therapeutics, Inc. (ALRN) Financial Statements (2024 and earlier)

Company Profile

Business Address 738 MAIN STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,666,00016,721,00021,242,00025,477,00032,382,00038,075,000
Cash and cash equivalents13,167,0007,783,0005,194,0004,839,0007,628,0007,449,000
Short-term investments 499,0008,938,00016,048,00020,638,00024,754,00030,626,000
Restricted cash and investments25,00025,00025,00025,00025,00025,000
Other undisclosed current assets261,000359,000606,0001,552,0001,143,0001,893,000
Total current assets:13,952,00017,105,00021,873,00027,054,00033,550,00039,993,000
Noncurrent Assets
Operating lease, right-of-use asset   40,00070,00098,000125,000
Property, plant and equipment39,00052,00070,00084,00098,000113,000
Other noncurrent assets   24,00024,00024,00024,000
Total noncurrent assets:39,00052,000134,000178,000220,000262,000
TOTAL ASSETS:13,991,00017,157,00022,007,00027,232,00033,770,00040,255,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities970,0001,413,0002,637,0003,604,0004,004,0002,061,000
Employee-related liabilities1,063,000702,000535,000
Accounts payable136,000458,0001,720,000945,0001,741,0001,023,000
Accrued liabilities834,000955,000917,0001,596,0001,561,000503,000
Restructuring reserve35,000992,000    
Other undisclosed current liabilities192,000479,000747,000932,0001,147,0002,085,000
Total current liabilities:1,197,0002,884,0003,384,0004,536,0005,151,0004,146,000
Noncurrent Liabilities
Total liabilities:1,197,0002,884,0003,384,0004,536,0005,151,0004,146,000
Equity
Equity, attributable to parent12,794,00014,273,00018,623,00022,696,00028,619,00036,109,000
Common stock91,00091,00091,00091,00091,00091,000
Additional paid in capital292,056,000291,756,000291,365,000290,941,000290,499,000289,971,000
Accumulated other comprehensive loss (2,000)(10,000)(48,000)(98,000)(101,000)(75,000)
Accumulated deficit(279,351,000)(277,564,000)(272,785,000)(268,238,000)(261,870,000)(253,878,000)
Total equity:12,794,00014,273,00018,623,00022,696,00028,619,00036,109,000
TOTAL LIABILITIES AND EQUITY:13,991,00017,157,00022,007,00027,232,00033,770,00040,255,000

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(1,992,000)(5,011,000)(4,703,000)(6,482,000)(8,041,000)(8,421,000)
Operating loss:(1,992,000)(5,011,000)(4,703,000)(6,482,000)(8,041,000)(8,421,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
93,000177,000336,0004,000 (22,000)
Loss from continuing operations:(1,899,000)(4,834,000)(4,367,000)(6,478,000)(8,041,000)(8,443,000)
Loss before gain (loss) on sale of properties:(6,478,000)(8,041,000)(8,443,000)
Other undisclosed net income (loss)  55,000(180,000)  21,000
Net loss:(1,899,000)(4,779,000)(4,547,000)(6,478,000)(8,041,000)(8,422,000)
Other undisclosed net income attributable to parent112,000  110,00049,000 
Net loss available to common stockholders, diluted:(1,787,000)(4,779,000)(4,547,000)(6,368,000)(7,992,000)(8,422,000)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(1,899,000)(4,779,000)(4,547,000)(6,478,000)(8,041,000)(8,422,000)
Comprehensive loss:(1,899,000)(4,779,000)(4,547,000)(6,478,000)(8,041,000)(8,422,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent120,00038,00050,000113,00023,000(62,000)
Comprehensive loss, net of tax, attributable to parent:(1,779,000)(4,741,000)(4,497,000)(6,365,000)(8,018,000)(8,484,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: